Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 16/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | AR | P10275 | 1/20 | 0.48 |
| ▸ | CTSB | P07858 | 1/20 | 0.46 |
| ▸ | BRD4 | O60885 | 1/20 | 0.46 |
| ▸ | ALPL | P05186 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17825233 | 0.87 | PARP1 (0.64) | PARP1CYP3A4CYP2C9TSHRCYP2C19 | |
| SCHEMBL17824806 | 0.81 | PARP1 (0.50) | PARP1CYP3A4CYP2C9TSHRCYP2C19 | |
| SCHEMBL4833670 | 0.81 | PARP1 (0.66) | PARP1CYP3A4CYP2C9TSHRCYP2C19 | |
| SCHEMBL17824973 | 0.81 | PARP1 (0.57) | PARP1CYP3A4CYP2C9TSHRCYP2C19 | |
| SCHEMBL4698502 | 0.81 | PARP1 (0.57) | PARP1CYP3A4CYP2C9TSHRCYP2C19 | |
| SCHEMBL28174263 | 0.77 | SCN9A (0.47) | CYP3A4CYP2C9CYP2C19CTSB | |
| SCHEMBL17824812 | 0.75 | PARP1 (0.46) | PARP1ARCTSB | |
| SCHEMBL15010308 | 0.75 | PDE4A (0.47) | CYP3A4CYP2C9TSHRCYP2C19AR | |
| SCHEMBL4754791 | 0.75 | PARP1 (0.59) | PARP1TSHR | |
| SCHEMBL17824752 | 0.74 | POLB (0.50) | CYP3A4CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10239843-B2 | 2,4-dioxo-quinazoline-6-sulfonamide derivatives as inhibitors of PARG | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2019-03-26 | — | — | US | disclosed |
| US-10239843-B2 | 2,4-dioxo-quinazoline-6-sulfonamide derivatives as inhibitors of PARG | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2019-03-26 | — | — | US | disclosed |
| US-20180016242-A1 | 2,4-DIOXO-QUINAZOLINE-6-SULFONAMIDE DERIVATIVES AS INHIBITORS OF PARG | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2018-01-18 | — | — | US | disclosed |
| US-20180016242-A1 | 2,4-DIOXO-QUINAZOLINE-6-SULFONAMIDE DERIVATIVES AS INHIBITORS OF PARG | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2018-01-18 | — | — | US | disclosed |
| US-20180016242-A1 | 2,4-DIOXO-QUINAZOLINE-6-SULFONAMIDE DERIVATIVES AS INHIBITORS OF PARG | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2018-01-18 | — | — | US | disclosed |
| EP-3230273-A1 | 2,4-DIOXO-QUINAZOLINE-6-SULFONAMIDE DERIVATIVES AS INHIBITORS OF PARG | Cancer Research Technology Ltd (GB) | 2017-10-18 | — | — | EP | disclosed |
| WO-2016092326-A1 | 2,4-DIOXO-QUINAZOLINE-6-SULFONAMIDE DERIVATIVES AS INHIBITORS OF PARG | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2016-06-16 | — | — | WO | disclosed |
| WO-2016092326-A1 | 2,4-DIOXO-QUINAZOLINE-6-SULFONAMIDE DERIVATIVES AS INHIBITORS OF PARG | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2016-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180016242-A1 | 2,4-DIOXO-QUINAZOLINE-6-SULFONAMIDE DERIVATIVES AS INHIBITORS OF PARG | PARG, PARP15, PARP12 | PARP1 8/4885CYP3A4 753/4885CYP2C9 1394/4885 |
| US-10239843-B2 | 2,4-dioxo-quinazoline-6-sulfonamide derivatives as inhibitors of PARG | PARG, PARP15, PARP12 | PARP1 8/4885CYP3A4 753/4885CYP2C9 1394/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.